Pancreatic Cancer
Articles tagged with Pancreatic Cancer
Cancer-causing protein also helps tumors repair their DNA
UT MD Anderson shares latest research breakthroughs
Rhein attenuates severe acute pancreatitis-associated intestinal injury through pparγ regulating macrophage activation
UMass Chan scientist Marcus Ruscetti receives 2026 Pershing Square Sohn Cancer Prize
Amplified Sciences enrolls patients in PanAMP real-world, multicenter clinical utility study
ASCO 2026 Tip Sheet - Sylvester Comprehensive Cancer Center
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Trinity researchers publish ‘playbook’ for understanding pancreatic cancer, one of the deadliest cancers
Researchers at Trinity College Dublin have published a comprehensive review of pancreatic cancer, explaining why it's resistant to treatment and where new hope may emerge. The study identifies multiple biological systems interacting to drive the disease's growth and suggests combination-based treatments targeting multiple hallmarks of ...
RAS(ON) inhibitor daraxonrasib shows promising results in advanced pancreatic cancer phase 1/2 study
A phase 1/2 trial of daraxonrasib, a RAS(ON) multi-selective inhibitor, demonstrated safety and broad activity against RAS-mutant metastatic pancreatic cancer. The drug showed promising signs of activity, with approximately 30% of patients experiencing an objective response and 90% experiencing disease control.
RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer
The Phase 1/2 trial demonstrated a 29% response rate and median overall survival of 15.6 months, outperforming historical chemotherapy response rates. Daraxonrasib targets RAS in its 'on' state and has shown durable responses with a manageable safety profile.
Common inflammatory genes link pancreatic cancer with obesity and diabetes
A study published in Cancer Medicine reveals that the same genes active in pancreatic cancer are also linked to obesity and diabetes, driving inflammatory and immune pathways. This discovery helps explain poorer cancer outcomes for those with metabolic disease and offers new avenues for targeted treatment.
Promising new technique uses nanoparticles to detect pancreatic cancer
Researchers at OHSU have developed a sophisticated blood test that can detect early signs of pancreatic cancer with a 97% accuracy rate, distinguishing it from benign conditions. The technique uses nanoparticles shed by tumors into blood, offering a non-invasive way to identify the disease.
Tumor-on-a-chip brings new insight to pancreatic cancer
A team of researchers has developed a 'tumor-on-a-chip' system designed to recreate the complex environment surrounding pancreatic tumors. The system, which combines patient-derived organoids with microfluidic technology, closely mimics the behavior of human pancreatic tumors and demonstrates potential for studying immune responses.
Mayo Clinic AI detects pancreatic cancer up to 3 years before diagnosis in landmark validation study
The Mayo Clinic AI model detects pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis, identifying subtle signs of disease. The model identified 73% of prediagnostic cancers at a median of about 16 months before diagnosis.
AI model detects very early normally ‘invisible’ tissue changes of pancreatic cancer
An AI model called REDMOD can pick up the very early subtle tissue changes of pancreatic ductal adenocarcinoma, which conventional imaging and the human eye find difficult to detect. The model detected 'invisible' signature of pre-clinical pancreatic cancer an average of 475 days before clinical diagnosis.
Targeted therapy drug shows early promise against KRAS-driven lung and pancreatic cancers
A first-in-human clinical trial found that setidegrasib, a targeted therapy drug, demonstrated early antitumor activity in advanced lung and pancreatic cancers. The therapy shrank tumors and delayed disease progression in some patients, providing a potential new treatment approach for KRAS G12D-driven cancers.
Researchers from The Wistar Institute and ChristianaCare identify promising new therapeutic target for pancreatic cancer
Researchers have discovered a vulnerability in pancreatic cancer that could be targeted as a potential therapy. Damaged mitochondria leak double-stranded RNA within cancer cells, causing inflammation that fuels cancer growth.
New scoring tool shows radiation can reprogram pancreatic tumor environment
A new composite scoring system, HOST-Factor, quantifies the functional state of the tumor microenvironment in pancreatic cancer. The study demonstrates the effectiveness of pulsed low-dose-rate chemoradiation in shifting the tumor microenvironment from a tumor-promoting to a tumor-restricting state.
Biosensor identifies pancreatic cancer in early stages
Researchers developed an electrochemical sensor to detect pancreatic cancer at low concentrations, improving accessibility and effectiveness of treatment. The device identifies CA19-9 protein, a key biomarker for the disease, allowing for early diagnosis and potentially increasing survival rates.
From benign growth to pancreatic cancer: New study shows how the switch gets flipped
A recent study published in Cell reveals the molecular mechanisms underlying the transformation of benign pancreatic cells into malignant tumors. Researchers identified a subset of precancerous cells that closely resemble tumor cells, characterized by high oncogenic drive and strongly activated tumor-suppressors. This discovery offers ...
Penn Medicine at the AACR Annual Meeting 2026
Researchers from Penn Medicine will showcase progress in CAR T cell therapies for solid tumors, as well as a multi-chain CAR T cell therapy for ovarian cancer. The presentation also highlights a new strategy targeting pancreatic cancer before it forms and at-home cervical cancer testing.
New drug doubles one-year survival in pancreatic cancer trial
A phase 2 clinical trial shows that a new drug, elraglusib, when combined with chemotherapy, doubles one-year survival rates in pancreatic cancer patients, reducing the risk of death by 38%. The study is a rare success in showing a survival benefit applicable to a broad population.
OHSU research reveals how pancreatic cancer blocks immunotherapy
Researchers at OHSU have uncovered that pancreatic tumors co-opt regulatory immune cells, leading to resistance against immunotherapy. A promising strategy involves reprogramming these cells to support anti-tumor activity, potentially making immunotherapy viable for treatment-resistant cancers.
AACR: Targeted drug delivery for colorectal cancer, COVID-19’s impact on breast cancer outcomes, AI in cancer diagnosis and more
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
UT MD Anderson shares latest research breakthroughs
Researchers at UT MD Anderson have made significant advancements in cancer care, including a blood-based biomarker for cancer risk in people with Lynch Syndrome and a new target to sensitize pancreatic tumors to immunotherapy. The studies also identified a strategy to overcome radiation therapy resistance in lung cancer.
Researchers find new target to sensitize pancreatic tumors to immunotherapy
A study published in Cancer Research has identified DPY30 as an epigenetic target that can sensitize pancreatic tumors to immunotherapy. By modulating DNA replication stress, DPY30 promotes the addition of activation signals at stressed replication forks, supporting cancer cell survival and proliferation.
Targeting tumor supporting cells: Advancing CAR T success in pancreatic cancer
Researchers have developed a new CAR T therapy that targets tumor-supporting cells in pancreatic cancer, paving the way for a potentially safer and more effective treatment. The therapy uses lipid nanoparticles to deliver CAR instructions directly to patient T cells, resulting in higher expression rates and improved efficacy compared t...
New insights into rare pancreatic tumors that cause low blood sugar
A study by researchers at Institute of Science Tokyo has identified a key gene, DOCK10, involved in abnormal insulin secretion in insulinomas. The findings pave the way for novel diagnostic biomarkers and treatment options.
New study reveals cellular communication driving chemotherapy resistance in pancreatic cancer
A new study has identified a PRRX2+ epithelial cell/SPP1+ macrophage axis that promotes gemcitabine resistance via TGF-β signaling in pancreatic cancer. The study suggests that targeting this cellular communication network may be key to overcoming drug resistance.
Sylvester Cancer Tip Sheet for March 2026
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
New strategy intercepts pancreatic cancer by eliminating microscopic lesions before they become cancer
Researchers developed an experimental therapy to target microscopic precancerous lesions in the pancreas, which nearly doubled survival in mouse models of pancreatic ductal adenocarcinoma. Long-term treatment with the therapy tripled median overall survival time compared to untreated mice.
IU researchers identify clotting protein as potential target in pancreatic cancer
Researchers found that depleting fibrinogen, a clotting protein, slows down pancreatic cancer by shrinking tumors and reducing liver metastasis. Fibrinogen contributes to tumor growth and environment, and its depletion changes tumor cells to alter behavior and aggressiveness.
Study finds stress-related nerves may fuel pancreatic cancer growth
Researchers at OHSU found that sympathetic nerves support pancreatic tumor growth by communicating with cancer cells and nearby fibroblasts. The study suggests that removing these nerves may lead to smaller tumors, particularly in female mice.
Scientists uncover molecular ‘switch’ that could make pancreatic cancer more treatable
Researchers identified a key gene GATA6 that helps control the 'switch' between aggressive and manageable states in pancreatic cancer cells. By targeting this pathway, combination therapies with standard chemotherapy may improve treatment outcomes.
Pancreatic cancer may begin hiding from the immune system earlier than we thought
Researchers found that early precancerous cells in pancreas gather into specific clusters and interact with immune cells, weakening the body's ability to fight them. The study provides fresh insight into how pancreatic cancer may begin taking shape years before it is clinically detected.
Financial strain of cancer treatment undermines hope and life satisfaction new study finds
A new study analyzing 519 patients with cancer reveals that financial toxicity significantly impacts not only finances but also psychological resources like hope and social support. As these resources weaken, overall life satisfaction declines.
ESE and ESPE launch joint transition of care guidance to improve outcomes for young people moving from child to adult endocrine care
The ESE and ESPE have launched a landmark Joint Clinical Practice Guidance to support structured and effective transition of young people with endocrine conditions. The Guidance provides practical, evidence-based recommendations to ensure continuity, safety and quality of care during this critical phase in a patient's life.
Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
Sensing local fibers in pancreatic tumors, cancer cells ‘choose’ to either grow or tolerate treatment
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.
Cancer Cell publication details development of cancer-induced cachexia and anorexia
Cancer cell researchers at the University of Oklahoma have developed a novel 'triangle regulation theory' that explains the development of cancer-induced cachexia and anorexia. The theory reveals how cancer cells recruit immune cells to trigger excess production of growth factor 15, leading to muscle wasting and loss of appetite.
New dual-action compound reduces pancreatic cancer cell growth
Researchers found that an experimental compound SB-216 reduced the growth of pancreatic ductal adenocarcinoma cells by inhibiting oncogenic microtubules and mitochondrial function. This approach may reduce cancer cell adaptation and survival.
Growth of spreading pancreatic cancer fueled by 'under-appreciated' epigenetic changes
A study published in Molecular Cancer found that the KLF5 gene plays a crucial role in fueling the growth of spreading pancreatic cancer by altering epigenetic changes. The researchers used CRISPR technology to silence genes and identified KLF5 as the most impactful gene associated with cell growth.
Let’s get on pancreatic cancer’s nerves
Scientists found that tumor-promoting fibroblasts attract nerve fibers through a vicious cycle of signaling and neurotransmitter release. This cycle promotes pre-cancerous growth and pulls in more nerve fibers, leading to a self-reinforcing loop. Disrupting this cycle may lead to new therapies for pancreatic cancer.
Mayo Clinic study finds chemotherapy before surgery improves survival in early-stage pancreatic cancer
Researchers found that when pancreatic tumors touch the superior mesenteric vein, patients who undergo surgery first experience reduced survival rates. In contrast, those who receive chemotherapy before surgery have similar survival outcomes to those with non-vein touching tumors. The study suggests reclassifying tumors based on vein i...
Pancreatic cancer cell atlas highlights why many promising treatments fail
A new study reveals that the surrounding microenvironment plays a crucial role in driving basal cell development, leading to treatment failure. The study also discovers intermediate tumor subtypes that could lead to new therapeutic strategies.
MSK research highlights, February 4, 2026
Researchers from Memorial Sloan Kettering Cancer Center reveal the origins of Thetis cells, which play a crucial role in teaching immune system tolerance. The team used single-nucleus DNA sequencing to shed light on pancreatic cancer evolution and identify genetic changes that occur earlier or later in disease progression.
A CNIO study completely eliminates pancreatic tumors in mice without resistance developing
A study published in PNAS successfully eliminated pancreatic tumours in mice completely and durably, with no significant side effects. The treatment, combining three molecular targets, induced robust regression of experimental PDACs without causing tumor resistance.
New AI tool helps doctors treat cancer patients after heart attack
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers identify new blood markers that may detect early pancreatic cancer
Researchers have developed a four-marker panel that can detect early-stage pancreatic cancer with high accuracy, potentially improving survival rates. The new test distinguishes cancer patients from healthy individuals and those with non-cancerous conditions, such as pancreatitis.
Investigational blood biomarker panel may improve detection of pancreatic cancer
A four-biomarker blood panel including aminopeptidase N, polymeric immunoglobulin receptor, and thrombospondin-2 has been shown to enhance the detection of pancreatic ductal adenocarcinoma compared to CA19-9 alone. The panel correctly detected 91.9% of pancreatic cancers across all stages.
Decoded: How cancer cells protect themselves from the immune system
Cancer researchers have identified a key mechanism by which cancer cells protect themselves from the immune system. The study found that MYC protein can bind to RNA molecules, eliminating alarm signals that would activate the immune defense.
Hollings researchers reveal why some pancreatic tumors behave differently
A study led by Aaron Hobbs and Rachel Burge reveals the distinct cell signaling and tumor microenvironment behind a slower-growing pancreatic tumor mutation. G12R KRAS mutations lead to better patient outcomes, including earlier diagnoses and longer survival times.
Lung cancer death rates among women in Europe are finally levelling off
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
Reversing immune suppression in pancreatic cancer could lead to novel therapies
Pancreatic cancer cells use specific microRNA molecules to reprogram nearby immune cells called macrophages, helping tumors grow. By blocking this communication, researchers found a potential way to reverse the process and restore macrophage function to fight cancer.
Potential tumor-suppressing gene identified in pancreatic cancer
The study reveals that low levels of CTDNEP1 drive early and deadly pancreatic tumors, highlighting its role as a tumor suppressor. Tumors with low CTDNEP1 expression showed stronger metabolic activity and immune evasion.
A study by CNIO identifies new genes that predispose an individual to pancreatic cancer
A new study by CNIO has identified two genes in the complement system that increase the risk of pancreatic ductal adenocarcinoma. These genes, FCN1 and PLAT, may serve as biomarkers for screening high-risk populations.
A new consensus classifyer for pancreatic cancer available online and as an app
A new consensus classifier for pancreatic cancer has been developed, enabling accurate determination of tumor subtypes and informing treatment choices. The tool also identifies risk factors for the disease, including smoking, which may be more significant in certain subtypes.
Short-circuiting pancreatic cancer
Researchers have discovered a complex regulatory circuit involving SRSF1, AURKA, and MYC that promotes aggressive pancreatic cancer progression. The circuit, which involves alternative splicing, can be targeted with an antisense oligonucleotide to reduce tumor cells' viability and trigger apoptosis.
UH pharmacy researcher receives $900,000 CPRIT grant to develop nanodrug that boosts immune system to fight cancer
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
Systematic review links pancreatic cancer surgery to postoperative diabetes risk
A systematic review found that pancreatic cancer surgery significantly increases the risk of new-onset diabetes mellitus (NODM), particularly in patients with known risk factors. The study analyzed 45 studies and found an overall incidence of NODM of 24.5%, with a higher rate in those who underwent distal pancreatectomy.